Hanna Eriksson

About me
Publications
CV
Public outreach and news

About me

Hanna Eriksson | Karolinska Institutet (ki.se)

Research

Cutaneous melanoma is one of the deadliest forms of skin cancer. The survival
is heterogenous both between and within disease stages. Early detection and
surgical removal of the primary melanoma is still crucial for the prognosis.
Landmark genomic and immunologic studies have translated into approved
targeted treatments and immunotherapies for metastatic disease. Targeted
therapies achieve high but often transient therapy responses. Immunotherapies
can achieve durable responses in a subset of patients. Serious immune
associated toxicities are a major clinical challenge.
Our overall objective is therefore to optimally inform clinical
decision-making and improve the outcome from early disease to advanced
melanoma.
Hanna Eriksson's Group | Karolinska Institutet (ki.se) [1]

Teaching

I am currently main-supervisor for PhD-students postodocs.
PhD course organizer for:
Clinical Oncology for Pre-Clinical Doctoral Students (#5505), Karolinska
Institutet.
Basic Course in Tumor Biology and Oncology (#3112), Karolinska Institutet.

Articles

Article: EUROPEAN JOURNAL OF CANCER. 2024;200:113601

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.

Egeler M; Lai-Kwon J; Tissier R; Fraterman I; Kuijpers A; Van Houdt W; Wilgenhof S; Rao A; Sandhu S; Lee R; Eriksson H; van Leeuwen M; de Ligt K; van Akkooi A; van de Poll-Franse L
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2024;:S0190-9622(24)00056-2

Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden: A population-based cohort study.

Vikström S; Syriopoulou E; Andersson TM-L; Eriksson H
Article: BRITISH JOURNAL OF DERMATOLOGY. 2023;189(6):702-709

Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.

Vikström S; Mikiver R; Lapins J; Nielsen K; Vassilaki I; Lyth J; Isaksson K; Eriksson H
Article: ANNALS OF ONCOLOGY. 2023;34(4):420-430

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
Article: BRITISH JOURNAL OF DERMATOLOGY. 2023;188(1):32-40

Association of metformin use and survival in patients with cutaneous melanoma and diabetes.

Krakowski I; Häbel H; Nielsen K; Ingvar C; Andersson TML; Girnita A; Smedby KE; Eriksson H
Article: CANCERS. 2022;14(3):702

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Costa Svedman F; Jalsenius M; Höiom V; Grozman V; Bergqvist M; Söderdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2022;386(1):24-34

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob J-J; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV; RELATIVITY-047 Investigators
Article: GENETICS IN MEDICINE. 2022;24(1):157-169

Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma.

Yang M; Johnsson P; Bräutigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engström PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Höiom V
Article: CANCERS. 2021;13(16):4164

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.

Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: NEOPLASIA. 2021;23(8):783-791

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.

Babačić H; Eriksson H; Pernemalm M
Article: CANCERS. 2021;13(11):2838

Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden.

Eriksson H; Nielsen K; Vassilaki I; Lapins J; Mikiver R; Lyth J; Isaksson K
Article: ANNALS OF ONCOLOGY. 2021;32(6):766-777

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

Rawson RV; Adhikari C; Bierman C; Lo SN; Shklovskaya E; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Gonzalez M; Guminski AD; Tetzlaff MT; Stretch JR; Eriksson H; van Thienen JV; Wouters MW; Haanen JBAG; Klop WMC; Zuur CL; van Houdt WJ; Nieweg OE; Ch'ng S; Rizos H; Saw RPM; Spillane AJ; Wilmott JS; Blank CU; Long GV; van de Wiel BA; Scolyer RA
Article: CANCERS. 2021;13(10):2456

The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden.

Eriksson H; Utjés D; Olofsson Bagge R; Gillgren P; Isaksson K; Lapins J; Schultz IL; Lyth J; Andersson TM-L
Article: NATURE MEDICINE. 2021;27(2):256-263

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU
Article: BRITISH JOURNAL OF DERMATOLOGY. 2021;184(1):60-67

Survival in 31 670 patients with thin melanomas: a Swedish population-based study.

Isaksson K; Mikiver R; Eriksson H; Lapins J; Nielsen K; Ingvar C; Lyth J
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.

Krakowski I; Bottai M; Häbel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: CANCERS. 2020;12(11):E3228-3228

The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study.

Katsarelias D; Eriksson H; Mikiver R; Krakowski I; Nilsson JA; Ny L; Olofsson Bagge R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(14):1591-1601

Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Maurichi A; Miceli R; Eriksson H; Newton-Bishop J; Nsengimana J; Chan M; Hayes AJ; Heelan K; Adams D; Patuzzo R; Barretta F; Gallino G; Harwood C; Bergamaschi D; Bennett D; Lasithiotakis K; Ghiorzo P; Dalmasso B; Manganoni A; Consoli F; Mattavelli I; Barbieri C; Leva A; Cortinovis U; Espeli V; Mangas C; Quaglino P; Ribero S; Broganelli P; Pellacani G; Longo C; Del Forno C; Borgognoni L; Sestini S; Pimpinelli N; Fortunato S; Chiarugi A; Nardini P; Morittu E; Florita A; Cossa M; Valeri B; Milione M; Pruneri G; Zoras O; Anichini A; Mortarini R; Santinami M
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(1):e000204

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.

Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
Article: FRONTIERS IN ONCOLOGY. 2020;10:51

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.

Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtiö J; Mole DJ; Hansson J; Eriksson H; Tegnér J
Article: LANCET. 2019;394(10197):471-477

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.

Utjés D; Malmstedt J; Teras J; Drzewiecki K; Gullestad HP; Ingvar C; Eriksson H; Gillgren P
Article: LANCET ONCOLOGY. 2019;20(7):948-960

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Article: CANCER RESEARCH. 2018;78(20):5970-5979

Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.

Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
Article: PLOS ONE. 2018;13(11):e0206942

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.

Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;141(11):2243-2252

Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study.

Utjés D; Lyth J; Lapins J; Eriksson H
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(9):1468-1474

Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.

Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
Article: LAKARTIDNINGEN. 2017;114:ELAT

[Every second hour there is a new melanoma diagnosed in Sweden].

Ingvar C; Eriksson H
Article: PIGMENT CELL & MELANOMA RESEARCH. 2017;30(1):76-156

13th International Congress of the Society for Melanoma Research, Boston, MA, USA, November 6-9, 2016 Abstracts
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(3):543-553

Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.

Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Article: GENES CHROMOSOMES & CANCER. 2016;55(7):601-611

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Tuominen R; Engström PG; Helgadottir H; Eriksson H; Unneberg P; Kjellqvist S; Yang M; Lindén D; Edsgärd D; Hansson J; Höiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;138(12):2829-2836

The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.

Eriksson H; Lyth J; Andersson TM-L
Article: JAMA DERMATOLOGY. 2015;151(4):410-416

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(3):700-706

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men.

Lyth J; Eriksson H; Hansson J; Ingvar C; Jansson M; Lapins J; Månsson-Brahme E; Naredi P; Stierner U; Ullenhag G; Carstensen J; Lindholm C
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(1):175-186

Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study.

Eriksson H; Frohm-Nilsson M; Järås J; Kanter-Lewensohn L; Kjellman P; Månsson-Brahme E; Vassilaki I; Hansson J
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2014;71(2):245-248

Risk of cutaneous malignant melanoma in patients with celiac disease: a population-based study.

Lebwohl B; Eriksson H; Hansson J; Green PHR; Ludvigsson JF
Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(13):1356-1364

Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J
Article: CANCER EPIDEMIOLOGY. 2014;38(1):93-99

Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study.

Andersson TM-L; Eriksson H; Hansson J; Månsson-Brahme E; Dickman PW; Eloranta S; Lambe M; Lambert PC
Article: PIGMENT CELL & MELANOMA RESEARCH. 2013;26(6):932-1019

10th International Congress of the Society for Melanoma Research, Philadelphia, PA, USA, November 17-20, 2013 Abstracts
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(12):2705-2716

Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.

Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Article: ACTA DERMATO-VENEREOLOGICA. 2013;93(4):411-416

Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management.

Eriksson H; Frohm-Nilsson M; Hedblad M-A; Hellborg H; Kanter-Lewensohn L; Krawiec K; Lundh Rozell B; Månsson-Brahme E; Hansson J
Article: GENES CHROMOSOMES & CANCER. 2013;52(4):378-384

Hereditary uveal melanoma: a report of a germline mutation in BAP1.

Höiom V; Edsgärd D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Article: ARCHIVES OF DERMATOLOGY. 2008;144(5):612-616

A retrospective analysis of patients with bullous pemphigoid treated with methotrexate.

Kjellman P; Eriksson H; Berg P
Show more

All other publications

Review: NPJ DIGITAL MEDICINE. 2024;7(1):78

Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis.

Krakowski I; Kim J; Cai ZR; Daneshjou R; Lapins J; Eriksson H; Lykou A; Linos E
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023;183:103919

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.

Egeler MD; van Leeuwen M; Fraterman I; van den Heuvel NMJ; Boekhout AH; Lai-Kwon J; Wilthagen EA; Eriksson H; Haanen JB; Wilgenhof S; Ascierto PA; van Akkooi ACJ; van de Poll-Franse LV
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersäll P; Edbäck U; Wickström S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzén B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: LAKARTIDNINGEN. 2021;118:21114

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].

Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Meeting abstract: ANNALS OF ONCOLOGY. 2021;32:S1223-S1224

Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment

Miceli R; Eriksson H; Eustace AJ; Lo Russo G; Ballot J; Bergamini C; Bjaanaes MM; Corti F; De Cecco L; Frisardi L; Giannatempo P; Verzoni E; Helland A; Crown JP
Corrigendum: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(6):1407

Corrigendum: Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.

Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Editorial comment: CANCERS. 2020;13(1):E92-92

Reply to Comment on Katsarelias, D., et al. "The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study." Cancers 2020, 12, 3228.

Katsarelias D; Eriksson H; Mikiver R; Krakowski I; Nilsson JA; Ny L; Olofsson Bagge R
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Meeting abstract: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8:A2

UPDATE OF THE OPACIN AND OPACIN-NEO TRIALS: 36-MONTHS AND 24-MONTHS RELAPSE-FREE SURVIVAL AFTER (NEO)ADJUVANT IPILIMUMAB PLUS NIVOLUMAB IN MACROSCOPIC STAGE III MELANOMA PATIENTS

Versluis JM; Rozeman EA; Menzies AM; Reijers ILM; Krijgsman O; Hoefsmit EP; de Wiel BAV; Sikorska K; Bierman C; Dimitriadis P; Gonzalez M; Broeks A; Kerkhoven RM; Spillane AJ; Haanen JBAG; van Houdt WJ; Saw RPM; Eriksson H; van Akkooi ACJ; Scolyer RA; Schumacher TN; Long GV; Blank CU
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(27):3238-3240

Reply to E. Hindié.

Maurichi A; Miceli R; Eriksson H; Newton-Bishop J; Nsengimana J; Chan M; Hayes AJ; Heelan K; Adams D; Patuzzo R; Barretta F; Gallino G; Harwood C; Bergamaschi D; Bennett D; Lasithiotakis K; Ghiorzo P; Dalmasso B; Manganoni A; Consoli F; Mattavelli I; Barbieri C; Leva A; Cortinovis U; Espeli V; Mangas C; Quaglino P; Ribero S; Broganelli P; Pellacani G; Longo C; Del Forno C; Borgognoni L; Sestini S; Pimpinelli N; Fortunato S; Chiarugi A; Nardini P; Morittu E; Florita A; Cossa M; Valeri B; Milione M; Pruneri G; Zoras O; Anichini A; Mortarini R; Santinami M
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S760

Plasma proteomics in patients with metastatic cutaneous melanoma treated with targeted therapy

Eriksson H; Babacic H; Lehtio J; Pernemalm M
Meeting abstract: CANCER RESEARCH. 2020;80(16):3412

36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

Blank CU; Versluis JM; Rozeman EA; Menzies AM; Reijers IL; Krijgsman O; Hoefsmit EP; van de Wiel BA; Sikorska K; Bierman C; Dimitriadis P; Gonzalez M; Broeks A; Kerkhoven RM; Spillane AJ; Haanen JB; van Houdt WJ; Saw RP; Eriksson H; van Akkooi AC; Scolyer RA; Schumacher TN; Long GV
Meeting abstract: CANCER RESEARCH. 2020;80(16):3271

Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial

Reijers IL; Rozeman EA; Menzies AM; Versluis JM; van de Wiel BA; Sikorska K; Eriksson H; Shannon K; Bierman C; van Tinteren H; Gonzalez M; Spillane AJ; Saw RP; van Akkooi AC; Scolyer RA; Hansson J; Long GV; Blank CU
Letter: ALLERGY. 2020;75(8):2096-2099

Desloratadine and loratadine use associated with improved melanoma survival.

Fritz I; Wagner P; Bottai M; Eriksson H; Ingvar C; Krakowski I; Nielsen K; Olsson H
Editorial comment: ACTA ONCOLOGICA. 2020;59(3):247-248

Immune checkpoint inhibitors in cancer treatment and potential effect modification by age.

Eriksson H; Smedby KE
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):tps9605

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

Reijers I; Rozeman EA; Menzies AM; Van de Wiel BA; Eriksson H; Suijkerbuijk K; Van der Veldt AAM; Kapiteijn E; Hospers G; Klop WMC; Spillane A; Scolyer RA; Svane IM; Bastholt L; Schmidt H; Larkin JMG; Van Akkooi ACJ; Long GV; Blank CU
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):9574

Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy.

Eriksson H; Babacic H; Lehtio J; Pernemalm M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e21587

Dissecting genetic heterogeneity in stage III cutaneous malignant melanoma with spatially resolved transcriptomics.

Eriksson H; Thrane K; Maaskola J; Hansson J; Lundeberg J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:tps9600

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Rozeman EA; Christopher A; Van Akkooi J; Routier E; Menzies AM; Eriksson H; Smith M; Scolyer RA; Hoeller C; Hansson J; Robert C; Larkin JMG; Long GV; Blank CU
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):9579

Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).

Eriksson H; Lohcharoenkal W; Costa-Svedman F; Sonkoly E; Brage SE; Hansson J; Pivarcsi A
KI thesis / dissertation: 2013

Clinical and epidemiological studies on prognostic and predicitve factors in cutaneous melanoma

Eriksson, Hanna
Show more

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska Institutet, 2021
Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2013
University Medical Degree, Karolinska Institutet, 2002

Supervisor

Anna Warnqvist, Loss of life expectancy for patients with malignant melanoma, by socioeconomic groups and sex, 2023

About me

Research

Teaching

Articles

All other publications

Employments

Degrees and Education

Supervisor

News from KI

Events from KI